Directorio

This study compares standard treatment that includes chemotherapy, hormone therapy, and ribociclib with a treatment that uses only hormone therapy and ribociclib. Researchers want to learn if chemotherapy is needed for all patients with this type of cancer.

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

We are doing this study to compare the results of typical chemotherapy on its own to high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. We want to know which option has the best outcomes for people with periperhal T-cell lymphoma.

If people join this study, they will be placed into one of two groups by chance. One group will have the usual surgery to remove the melanoma along with a procedure to check nearby lymph nodes. The other group will have only the surgery to remove the melanoma. After surgery, doctors will watch for any signs that the melanoma has come back. Participants will complete surveys about their health and quality of life every four months for the first two years. After that, they will continue seeing their doctors every six months for three more years. If the melanoma returns after the first two years, participants will be asked to complete another survey at that time.

We are doing this study to compare the usual treatments of surgery alone to using chemotherapy before surgery. We want to know if adding doxorubicin and ifosfamide chemotherapy for liposarcoma (LPS) or doxorubicin and dacarbazine chemotherapy for leiomyosarcoma (LMS) before surgery can improve the long-term survival for patients with these cancers.

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).

Taking part in this study involves one visit that lasts about thirty minutes. During the visit, participants will answer a short survey about their health and hearing. They will also give a small saliva sample and have a gentle swab placed in the nose. These steps do not hurt. The visit can be done in person at a clinic or another location, or sometimes from home if the person lives nearby. There is no cost to take part, and there is no payment for joining the study.